A Study of CFTR modulator combination therapy for people Heterozygous for the F508del Mutation and a Minimal Function Mutation (VX-659)
Details
- Therapeutic approach
- Restore CFTR Function
- Trial status
- Closed with results Participating Centres
- Trials Tracker ID
- TT001861
- Last updated
- 17/10/2019
Full title
A Phase 3, Randomised, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
Study detailsA Phase 3, Randomised, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
- Phase
- Phase 3
- Length of participation
- 24 weeks
- Recruitment target
- 360
- CF sponsor
- Vertex Pharmaceuticals Incorporated
- CF sponsor type
- Commercial
Who can take part?
- Age range
- 12 years and older
- Including people
Age 12 years or older
Heterozygous for F508del and a minimal function mutation
FEV1 value ≥40% and ≤90% of predicted mean for age, sex, and height
Get in touch